Efficacy and safety of azithromycin 1.5% eye drops for purulent bacterial conjunctivitis in pediatric patients

Pediatric Infectious Disease Journal

Volumn 29, Issue 3, 2010, Pages 222-226

  Bremond Gignac, Dominique ^a   Mariani Kurkdjian, Patricia ^b   Beresniak, Ariel ^c   El Fekih, Lamia ^d   Bhagat, Yasmin ^e   Pouliquen, Pascale ^f   Delval, Laurent ^g   Goldschmidt, Pablo ^h   Bingen, Edouard ^a   Cochereau, Isabelle ⁱ  

^a UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

^b HÔPITAL ROBERT DEBRÉ   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d DATA MINING INTERNATIONAL   (Switzerland)

^e Hopital des Forces de Securite Interieure de la Marsa   (Tunisia)

^f Saint George Hospital   (India)

^g Laboratoires Thea   (France)

^h Hopital des XV XX   (France)

ⁱ BICHAT HOSPITAL   (France)

Author keywords

Azithromycin eye drops; Bacterial conjunctivitis; Children; Short treatment course

Indexed keywords

AZITHROMYCIN; AZYTER; EYE DROPS; TOBRAMYCIN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM CULTURE; BLURRED VISION; BURNING SENSATION; CHILD; CLINICAL TRIAL; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; ERADICATION THERAPY; EYE; FEMALE; FOREIGN BODY SENSATION; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEWBORN; OCULAR PRURITUS; PRESCHOOL CHILD; PRIORITY JOURNAL; PURULENT BACTERIAL CONJUNCTIVITIS; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SENSORY DYSFUNCTION; STICKINESS; STINGING SENSATION; SUPPURATION; SYMPTOM;

EID: 77649205437     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3181b99fa2     Document Type: Article

References (35)

1. Syed NA, Chandler JW. Bacterial conjunctivitis. In: Tabbara KF, Hyndiuk RA, eds. Infections of the Eye. Boston, MA: Little, Brown and Co; 1996:423-431.
2. Gigliotti F, Hendley JO, Morgan J, et al. Efficacy of topical antibiotic therapy in acute conjunctivitis in children. J Pediatr. 1984;104:623-626.
3. Gross RD, Hoffman RO, Lindsay RN. A comparison of ciprofloxacin and tobramycin in bacterial conjunctivitis in children. Clin Pediatr (Phila). 1997;36:435-444.
4. Lichtenstein SJ, Rinehart M. Efficacy and safety of 0.5% levofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis in pediatric patients. J AAPOS. 2003;7:317-324.
5. Soukiasian SH, Baum J. Bacterial conjunctivitis. In: Krachmer JH, Mannis MJ, Holland EJ, eds. Cornea. 2nd ed. Philadelphia, PA: Elsevier Mosby; 2005:615-628.
6. Hwang DG. Bacterial conjunctivitis. In: Pepose JS, Holland GN, Wilhel-mus KR, eds. Ocular Infection & Immunity. Saint-Louis, MO: Mosby; 1996:799-817.
7. Martin M, Turco JH, Zegans ME, et al. An outbreak of conjunctivitis due to atypical Streptococcus pneumoniae. N Engl J Med. 2003;348:1112-1121.
8. Sheikh A, Hurwitz B, Cave J. Antibiotics versus placebo for acute bacterial conjunctivitis. Cochrane Database Syst Rev. 2000:CD001211.
9. Sheikh A, Hurwitz B. Topical antibiotics for acute bacterial conjunctivitis: a systematic review. Br J Gen Pract. 2001;51:473-477. (Pubitemid 32509650)
10. Sheikh A, Hurwitz B. Antibiotics versus placebo for acute bacterial conjunctivitis. Cochrane Database Syst Rev. 2006;CD001211.
11. Hwang DG, Schanzlin DJ, Rotberg MH, et al. A phase III, placebo controlled clinical trial of 0.5% levofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis. Br J Ophthalmol. 2003;87:1004-1009.
12. Leibowitz HM. Antibacterial effectiveness of ciprofloxacin 0.3% ophthalmic solution in the treatment of bacterial conjunctivitis. Am J Ophthalmol. 1991;112:29S-33S.
13. Sheikh A. Acute bacterial conjunctivitis. In: Wormald R, Smeeth L, Henshaw K, eds. Evidence-Based Ophthalmology. London, United Kingdom: BMJ Books; 2004:33-35.
14. The European Agency for the Evaluation of Medicinal Products (EMEA). Committee for Proprietary Medicinal Products (CPMP). ICH Topic E11: Clinical Investigation of Medicinal Products in the Paediatric Population. Note for Guidance on Clinical Investigation of Medicinal Products in the Paediatric Population. CPMP/ICH/2711/99. London, United Kingdom: The European Agency for the Evaluation of Medicinal Products (EMEA); 2000:1-12.
15. Bloom PA, Leeming JP, Power W, et al. Topical ciprofloxacin in the treatment of blepharitis and blepharoconjunctivitis. Eur J Ophthalmol. 1994;4:6-12.
16. Cagle G, Davis S, Rosenthal A, et al. Topical tobramycin and gentamicin sulfate in the treatment of ocular infections: multicenter study. Curr Eye Res. 1981;1:523-534.
17. Cagle GD, Abshire RL. Quantitative ocular bacteriology: a method for the enumeration and identification of bacteria from the skin-lash margin and conjunctiva. Invest Ophthalmol Vis Sci. 1981;20:751-757.
18. Gwon A. Ofloxacin vs tobramycin for the treatment of external ocular infection. Ofloxacin Study Group II. Arch Ophthalmol. 1992;110:1234-1237.
19. Jacobson JA, Call NB, Kasworm EM, et al. Safety and efficacy of topical norfloxacin versus tobramycin in the treatment of external ocular infections. Antimicrob Agents Chemother. 1988;32:1820-1824.
20. Jauch A, Fsadni M, Gamba G. Meta-analysis of six clinical phase III studies comparing lomefloxacin 0.3% eye drops twice daily to five standard antibiotics in patients with acute bacterial conjunctivitis. Graefes Arch Clin Exp Ophthalmol. 1999;237:705-713.
21. Milazzo G, Papa V, Carstocea B, et al. Topical netilmicin compared with tobramycin in the treatment of external ocular infection. Int J Clin Pharmacol Ther. 1999;37:243-248.
22. Zou GY, Donner A. Construction of confidence limits about effect measures: a general approach. Stat Med. 2008;27:1693-1702.
23. Bosanquet N, Domenighetti G, Beresniak A, et al. Equity, access and economic evaluation in rare diseases: the impact of orphan drug legislation on health policy and patient care. Pharmaceut Dev Regul. 2003;1:151-157.
24. Council for International Organizations of Medical Sciences WGOPC. Pharmacogenetics: Towards Improving Treatment With Medicines. Geneva, Switzerland: CIOMS; 2005 1-224.
25. All AB, Golstein FW, Acar JF. In vitro activity of macrolides against traditional susceptible bacteria. In: Schönfeld W, Kirst HA, eds. Macrolide Antibiotics. Basel, Switzerland: Birkhaüser Verlag; 2002:185-200.
26. Drew RH, Gallis HA. Azithromycin-spectrum of activity, pharmacokinet-ics, and clinical applications. Pharmacotherapy. 1992;12:161-173.
27. Jain R, Danziger LH. The macrolide antibiotics: a pharmacokinetic and pharmacodynamic overview. Curr Pharm Des. 2004;10:3045-3053.
28. Peters DH, Friedel HA, McTavish D. Azithromycin. A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy. Drugs. 1992;44:750-799.
29. Zhanel GG, Dueck M, Hoban DJ, et al. Review of macrolides and ketolides: focus on respiratory tract infections. Drugs. 2001;61:443-498.
30. Zuckerman JM. Macrolides and ketolides: azithromycin, clarithromycin, telithromycin. Infect Dis Clin North Am. 2004;18:621-649.
31. Jaruratanasirikul S, Hortiwakul R, Tantisarasart T, et al. Distribution of azithromycin into brain tissue, cerebrospinal fluid, and aqueous humor of the eye. Antimicrob Agents Chemother. 1996;40:825-826.
32. Retsema J, Girard A, Schelkly W, et al. Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms. Antimicrob Agents Che-mother. 1987;31:1939-1947.
33. Tabbara KF, al-Kharashi SA, al-Mansouri SM, et al. Ocular levels of azithromycin. Arch Ophthalmol. 1998;116:1625-1628.
34. Cochereau I, Meddeb-Ouertani A, Khairallah M, et al. 3-day treatment with azithromycin 1.5% eye drops versus 7-day treatment with tobramycin 0.3% for purulent bacterial conjunctivitis: multicentre, randomised and controlled trial in adults and children. Br J Ophthalmol. 2007;91:465-469.
35. Cochereau I, Goldschmidt P, Goepogui A, et al. Efficacy and safety of short duration azithromycin eye drops versus azithromycin single oral dose for the treatment of trachoma in children-a randomised, controlled, double-masked clinical trial. Br J Ophthalmol. 2006;91:667-672.